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Abstract
Varying degrees of liver injuries have been reported in patients infected with the 
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). In general, 
oxidative stress is actively involved in initiation and progression of liver damage. 
The liver metabolizes various compounds that produce free radicals. Maintaining 
the oxidative/antioxidative balance is important in coronavirus disease 2019 
(COVID-19) patients. Antioxidant vitamins, essential trace elements and food 
compounds, such as polyphenols, appear to be promising agents, with effects in 
oxidative burst. Deficiency of these nutrients suppresses immune function and 
increases susceptibility to COVID-19. Daily micronutrient intake is necessary to 
support anti-inflammatory and antioxidative effects but for immune function may 
be higher than current recommended dietary intake. Antioxidant supplements (β-
carotene, vitamin A, vitamin C, vitamin E, and selenium) could have a potential 
role in patients with liver damage. Available evidence suggests that supple-
menting the diet with a combination of micronutrients may help to optimize 
immune function and reduce the risk of infection. Clinical trials based on the 
associations of diet and SARS-CoV-2 infection are lacking. Unfortunately, it is not 
possible to definitively determine the dose, route of administration and best 
timing to intervene with antioxidants in COVID-19 patients because clinical trials 
are still ongoing. Until then, hopefully, this review will enable clinicians to 
understand the impact of micronutrient dietary intake and liver status assessment 
in COVID-19 patients.
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Since its first appearance in December 2019 in Wuhan, China, coronavirus disease 2019 
(COVID-19), caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-
CoV-2), has spread swiftly around the world. The angiotensin converting enzyme 2 
(ACE2) receptor has been identified as the target vehicle for the virus entrance into the 
host cell[1]. After binding of SARS-CoV-2, the bioavailability of ACE2 is reduced and 
angiotensin 2 becomes extremely available to promote oxidative stress cascades and 
inflammatory responses, which in turn contribute to the pathological host responses 
and the severity of disease[2,3]. The multiple organ involvement is mainly attributed 
to the wide distribution of ACE2 receptors[4]. Incidence of liver injury in SARS-CoV-
2–infected patients is about 36% (range: 21%–52%)[1].
Any liver damage occurring during the COVID-19 course or treatment, in patients 
with or without previous liver diseases, could be considered as COVID-19-associated 
liver injury[4]. The presence of ACE2 receptors in hepatic cholangiocytes has pointed 
out the possibility of direct infection and active SARS-CoV-2 replication in the liver[5]. 
Many studies have also shown that COVID-19-associated liver injuries can be induced 
and/or exacerbated by the inflammatory response, endothelial changes, hypoxia and 
coagulopathy characteristic of severe disease course[4]. Accordingly, higher rates of 
liver dysfunction have been detected in critically ill COVID-19 patients[6]. In addition, 
compatibility between histological alternations and impaired blood flow has been 
found through the post-mortem analysis of COVID-19 patients’ liver samples. Marked 
derangement of intrahepatic blood vessels, including portal vein fibrosis and wall 
inflammation, herniated portal vein with activated Kupffer cells containing large 
necrotic debris, and vascular thrombosis accompanied with high D-dimer (≥ 500 
ng/dL) and high platelet count, have been observed[7].
In addition to impaired blood flow, more than a 50% of post-mortem liver samples 
of COVID-19 patients have shown the presence of large, small or mixed fatty droplets 
in hepatic parenchyma, a condition known as hepatic steatosis[7]. More recently, the 
hepatic steatosis, which is commonly associated with comorbidities such as metabolic 
syndrome, diabetes, obesity and hypertension, has also been recognized as an 
independent risk factor for severe disease in patients with COVID-19, significantly 
contributing to greater incidence of critical illness and lethality[8].
POSSIBLE MECHANISMS OF LIVER INJURY IN COVID-19 
The main biochemical findings in COVID-19-affected liver are elevated transaminase 
aspartate aminotransferase (commonly referred to as AST) and alanine transaminase 
(ALT), which are above referent range in 20.0%-22.5% and 14.6%-20.1% COVID-19 
cases, respectively. The increase of AST and ALT is followed by slightly increased total 
bilirubin in 35% of cases, as well as elevated alkaline phosphatase and gamma-
glutamyl transferase in 6.1% and 21.1% of COVID-19 patients, respectively[4]. A meta-
analysis of 25 relevant studies showed that COVID-19 survivors accounted for a lower 
percent of patients and lower increase of these parameters, compared with non-
survivors. Moreover, cured patients had lower levels of total bilirubin and lactate 
dehydrogenase, higher level of albumin and lower proportion of markedly decreased 
albumin than patients who succumbed to the disease[9].
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Until now, proposed mechanisms of COVID-19-associated liver injuries are: (1) 
Systemic inflammatory response; (2) Hypoxia–reperfusion injury; (3) Drug-induced 
liver injury; (4) Direct viral infection; and (5) Coexisting chronic liver disease [non-
alcoholic fatty liver disease (NAFLD), alcoholic liver disease (commonly referred to as 
ALD), hepatitis B virus and/or hepatitis C virus infection, hepatocellular carcinoma, 
etc.] (Figure 1).
Systemic inflammatory response is an extensive body inflammatory activity. It 
begins when SARS-CoV-2 lung infection activates alveolar macrophages and lung 
epithelial cells to promote massive release of proinflammatory cytokines, particularly 
interleukin (IL)-6, tumor necrosis factor (TNF), and IL-1β[10]. Acting locally, these 
cytokines increase permeability of the lung endothelium and support further dissem-
ination of the pathogen, but after reaching the circulation they spread through the 
body and induce excessive immune response, with deleterious impact on many organs 
(Figure 1). Proinflammatory cytokines further hyperactivate monocytes, macrophages 
and T lymphocytes, generating a self-producing loop which results in cytokines 
overwhelming the system [i.e. cytokine storm syndrome (also known as CSS)]. Thus, 
the cytokine storm can result in multiorgan damage, including to the liver[2].
In addition to CSS, hypoxia, as a consequence of pulmonary failure, is one of the 
most important factors causing secondary liver injury in COVID-19 patients[11]. Low 
or no circulation, reduced oxygen supply and lipid accumulation in hepatocytes 
during shock, and the hypoxic state lead to marked increases in reactive oxygen 
species (ROS) and their peroxidation products[12]. These hypoxia-induced products 
are directly involved in hepatic cell damage and death (Figure 1); while, on the other 
hand, they can act as second messengers to activate redox-sensitive transcription 
factors. They exaggerate the release of multiple proinflammatory factors and cause 
hepatocyte apoptosis, followed by further infiltration of inflammatory cells into 
hepatic tissue and consequent liver damage/failure[13]. However, the main part of 
liver injury caused by disturbed blood flow occurs during reperfusion, rather than at 
the time of the hypoxic state[14].
During the course of the COVID-19 epidemic, infected patients have been treated 
with different antipyretics (e.g., paracetamol, ibuprofen), analgetics (e.g., caffeine), anti-
inflammatory agents (e.g., aminosalicylates, corticosteroids), antirheumatics (e.g., 
chloroquine, hydroxychloroquine) and antiviral agents (e.g., baricitinib, abidol, 
lopinavir, ritonavir, remdesivir), and many of these drugs are hepatotoxic[15]. 
However, despite reports on more frequent liver injuries in critically ill COVID-19 
patients[11,16,17], there is no evidence on liver dysfunction induced exclusively by 
drugs in severe SARS-CoV-2 infection.
Abundant expression of ACE2 receptors makes the liver susceptible to direct 
infection by SARS-CoV-2[1,11]. Up-regulated expression of ACE2 receptors in 
hepatocytes of COVID-19 patients that suffer from severe hypoxia has also been 
found. Yet, there is no evidence of viral replication inside hepatocytes. On the other 
side, the liver harbors the body’s largest macrophage pool, indicating that the liver 
damage may be caused by lymphocytes recognizing infected hepatocytes and 
consequently inducing a cell death process[1].
OXIDATIVE STRESS, LIVER DISEASES AND COVID-19
Oxidative stress plays an important role in liver diseases. Although both ROS and 
reactive nitrogen species (RNS) are involved in normal physiological processes, 
excessive amounts of either can destroy the major cellular components, proteins, 
lipids, and DNA. Chronic liver diseases are one of the biggest risk factors for liver 
complications in COVID-19, and commonly these diseases are marked by increased 
oxidative stress[18]. In chronic liver diseases, function in all types of cells is altered 
including hepatocyte, stellate, endothelial and Kupffer cells and their impaired gene 
expression led to increased liver damage[19]. Oxidative stress and mitochondrial 
dysfunction have a key role in the development of NAFLD. Mitochondrial dysfunction 
implies not only the formation of ROS and RNS, glutathione (GSH) depletion, and 
protein oxidation but also inhibition of the β-oxidation of lipids, increased steatosis, 
and lipid accumulation in hepatocytes[18]. ROS are generated in a lipid-rich 
environment, leading to lipid peroxidation (LPO) and further production and release 
of very reactive products of LPO. These LPO products impair the respiratory chain in 
hepatocytes, leading to impaired oxidative phosphorylation, reduced ATP synthesis, 
and further increase ROS production[20]. Moreover, ROS, along with products of LPO, 
induce activation of several cytokines, including TNF-α, IL-6 and IL-8, as well as cell 
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Figure 1 Pathophysiological mechanisms of coronavirus disease 2019-associated liver injuries. Created with BioRender.com. ACE2: Angiotensin 
converting enzyme 2; ALP: Alkaline phosphatase; ALT: Alanine transaminase; AST: Aspartate aminotransferase; CSS: Cytokine storm syndrome; DILI: Drug-induced 
liver injury; GGT: Gamma-glutamyl transferase; ROS: Reactive oxygen species.
death and fibrosis[21]. Furthermore, decreased activity of antioxidative enzymes, 
particularly superoxide dismutase and catalase, and lower level of coenzyme Q10 had 
been noticed in patients with liver diseases[22].
Most mechanisms of tissue damage due to SARS-CoV-2 infection are directly 
associated with oxidative stress[23]. Nevertheless, according to our knowledge, there 
are no studies about the parameters of oxidative stress in patients with SARS-CoV-2 
infection. However, Polonikov et al[24] recently showed that people who had lower 
GSH levels before infection developed a more severe form of the disease than those 
with optimal GSH levels and suggested the crucial role of GSH in determining 
individual responsiveness to SARS-CoV-2 infection and disease pathogenesis.
In addition to producing O2 and H2O2, the cell infected by SARS-CoV-2 also 
produces IL-18 and IL-1β[2]. Besides, T lymphocytes and natural killer (NK) cells 
produce TNF-α, interferon (IFN)-γ, and IL-1β and stimulate the production of other 
proinflammatory cytokines, including IL-6 which contributes to the cytokine storm
[25]. Additionally, IL-6 acts on liver cells, which in turn increase the synthesis of 
fibrinogen, plasminogen activator inhibitor-1, and C-reactive protein (CRP). The levels 
of these molecules rise consistently in COVID-19 patients[26]. Since liver diseases are 
associated with disturbed redox balance and inflammation, SARS-CoV-2 infection can 
lead to serious manifestations and lethality in COVID-19 patients.
Considering that the more recent studies recognize oxidative stress as a key player 
in COVID-19 severity, the free radical scavenging by specific natural and/or synthetic 
antioxidants would be beneficial in preventing the progression of COVID-19[23]. 
Among others, some natural plant compounds, such as polyphenols, are known to 
have anti-inflammatory, antioxidative and antiapoptotic properties[27,28] that make 
them potentially beneficial in the effort to improve therapies for the most vulnerable 
SARS-CoV-2-infected patients.
ANTIOXIDANT NUTRIENTS, DIET AND COVID-19 
Vitamins and minerals are actively involved in neutralizing the harmful effects of 
oxidative species that induce liver damages. Their deficiency suppresses immune 
function and increases to the risk of infection. Patients with liver steatosis have 
increased LPO markers and proinflammatory cytokines as well as reduced total 
plasma antioxidant capacity (TAC)[29]. Literature data presented that vitamins (A, C, 
D, E, B6, B12, and folate), omega-3 fatty acids and minerals such as zinc, selenium, 
iron, magnesium and copper have important and common roles in maintaining the 
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immune system[30]. Inadequate dietary intake and/ or status of these micronutrients 
contribute to a decrease in resistance to infections, and consequently increased disease 
burden[31]. Zhang and Liu[32] pointed out that in the assessment of micronutrients 
besides vitamins A, D, B, C and omega-3 fatty acids in COVID-19 patients, trace 
elements (selenium, zinc, and iron) should also be considered. Anti-inflammatory 
dietary index and dietary TAC are emphasized as a concept of the association between 
nutrients, dietary sources, eating habits, inflammation, and oxidative stress[33,34]. 
Omega-3 fatty acids, vitamin A and vitamin C, as well as polyphenols (widely present 
in plant-based foods) are known nutritional ingredients with anti-inflammatory and 
antioxidant properties[35]. There is evidence that supplementation with higher daily 
doses of nutrients (vitamins D, C, E, zinc and omega-3 fatty acids) than recommended 
might have a beneficial effect in patients with COVID-19, potentially reducing the viral 
load and the duration of hospitalization[31,36-38]. Oxidative stress contributes to the 
onset and progression of liver damage through related pathological mechanism[35]. 
According to a recent study by de Oliveira et al[39] NAFLD patients with lower 
hepatic injury have higher dietary TAC.  It suggests a that increased consumption  of 
foods with naturally high TAC leads to reduced production of LPO[39].
Vitamin A
Liver injury is associated with impaired vitamin A homeostasis. Vitamin A plays a role 
in regulating the production of IL-2 (promoting T cell growth) and proinflammatory 
TNF-α, which activates the microbial action of macrophages[31]. Also, vitamin A is 
involved in the phagocytic and oxidative explosive activities of macrophages activated 
during inflammation[40]. Vitamin A and some other retinoids show important 
immunomodulatory properties, by increasing the efficiency of actions of type 1 IFNs (
e.g., IFN-I), which are important antiviral cytokines[41]. Thus, retinoids promoted 
increase antiviral responses mediated by IFN-I. There is evidence that activation of 
retinoid signaling can strongly inhibit coronaviruses[42]. Thus, retinoids could 
possibly suppress viral replication in COVID-19 patients and may interfere with the 
cellular uptake of SARS-CoV-2 by inhibiting ACE2[43].
Dietary plant sources of vitamin A are carotenoids, such as β-carotene, while animal 
sources are rich in retinyl esters. Major food sources of vitamin A are presented in 
Table 1. β-carotene is known as a scavenger of ROS[44]. It also enhances T lymphocyte 
response, NK cell activity, and IL-2 production[45]. Liver represents the largest pool of 
retinyl esters in hepatic stellate cells. In hepatitis C-infected patients, vitamin A 
deficiency is associated with a lack of response to IFN as antiviral therapy[46]. Further, 
NAFLD is associated with declining circulating and hepatic retinol levels[30], and 
patients with NAFLD have higher risk for SARS-CoV-2 infections[47]. Adequate daily 
intake (about 650 μg/d for women and 750 μg/d for men) and liver storage below 80% 
in a healthy person are required to keep retinol levels in plasma around 2 µmol/L[45]. 
Data from 10 western European countries, demonstrated that low levels of vitamin A 
are associated with the incidence and mortality of COVID-19[41]. Vitamin A deficiency 
can occur during SARS-CoV-2 infection due to effects on the lung and liver body 
stores caused by inflammation process[48], suggesting importance of supplementation 
during this disease[49].
Vitamin D 
Vitamin D is involved in several functions in the body, including increasing the 
oxidative burst potential of macrophages, and biosynthesis of superoxide dismutase. 
Furthermore, it suppresses the expression of proinflammatory cytokines, while 
promotes the expression of anti-inflammatory cytokines. In patients with chronic liver 
diseases, vitamin D deficiency is often reported[50], due to impaired synthesis of 
vitamin D–binding protein and hydroxylation of vitamin D. In spite of available in 
vitro and in vivo evidence, the therapeutic effect of vitamin D in liver disease still 
remain controversial[51]. Further studies will be required to clarify whether vitamin D 
have beneficial effects on liver diseases.
Vitamin D is actively involved in antioxidant, immunomodulatory, and antiviral 
responses. It induces the expression of enzymes involved in the antioxidant defense 
system. Also, it increases the levels of GSH, and suppresses the expression of NADPH 
oxidase. This way, vitamin D affects the reduction of oxidative stress and cellular 
oxidation[2]. Since deficiency of vitamin D is a global health challenge, the need for 
vitamin D supplementation has been a notable topic of research and discussion during 
the COVID-19 pandemic. Further, vitamin D deficiency elevates the vulnerability to 
acute viral respiratory infections[52]. Thus, supplementation with vitamin D enhances 
the innate immune responses to influenza and viral hepatitis C[53,54]. Vitamin D 
receptor is also expressed in pulmonary tissue.
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Table 1 Ongoing clinical trials of antioxidant supplementation in coronavirus disease 2019 patients
Antioxidants 
and nutrients
Plant and/or animal 
sources Potential target pathways
Recommended 
dietary intake; 
Effective dose for 
respiratory infection)
Registered clinical trials 
of COVID-19, rial number Intervention dose Primary outcome 
Vitamin A Carrots (raw); Cantaloupe; 
Mango; Salmon; Eggs
Role in immune competence; 
Immunomodulatory action
900/700 μg M/F IRCT20200319046819N1[49] 25000 IU vitamin A and 600000 IU 
vitamin D per day, 300 IU vitamin E 
twice a week, 2000 mg vitamin C 4 
times in a day, amp vitamin B; Soluvit 
in a day, for 1 wk
Weight, height, BMI; Severity of 
pulmonary involvement (CT scan); 
Respiratory support (invasive or non-
invasive); WBC, CRP, IL6, TNF-α, IFN-γ, 
ESR; Body temperature; Organ 
involvement; Hospital duration; 
Mortality
NCT04334005[61] 25000 IU vitamin D Mortality, all-cause mortality within 14 d
NCT04344041[62] 400000 IU/or 50000 IU Serum 25(OH)D3 changes during 
treatment
NCT04636086[63] 50000 IU vitamin D ; 25000 IU vitamin 
D ; Days 1-4, 8,15, 22, 29 and 36
Vitamin D serum concentration, clinical 
improvement, biological markers
NCT04621058[64] D deficiency (< 30 ng/mL) 0.532 mg 
vitamin D (< 40 ng/mL): 0.266 mg 
vitamin D
Mortality reduction, lent of hospital 
reduction
NCT04483635[65] 100000 IU vitamin D tab. baseline + 
10000 IU/wk; 16 wk 
Change in incidence laboratory-
confirmed COVID-19 infection
Vitamin D Portabella mushrooms; 
Dairy products; Eggs; Fish
Maintenance of cell physical barrier integrity; 
Increased antimicrobial protein production; 
Anti-inflammatory state; ACE2 and other 
members of the RAS expression
5- 15 μg; 20-50 μg[60]
NCT04386850[66] 25 µg 25(OH)D3; 2 mo Hospitalization, disease duration, death, 
mortality, ventilation
NCT04323514[74] 10 g vitamin C infusion Hospital mortality
NCT04530539[75] 1000 mg vitamin C Severity of symptoms 
Vitamin C Oranges; Lemon; Green 
and red peppers; Tomato; 
Broccoli; Brussel sprouts; 
Cabbage; Cauliflower; 
Spinach; Sweet potato; 
Winter squash
Antioxidant capacity; Immunomodulatory 
effects on interferon production; Cytokine 
production down-regulation
40-80 mg; 6–8 g[77]
NCT04682574[76] 30 g/d 2 d with standard treatment Partial pressure of oxygen in arterial 
blood to fraction of inspired oxygen 
Vitamin E Sunflower seeds; Nuts; 
Almonds; Blueberries; Kivi; 
Broccoli
Antioxidant action; Immunomodulatory effects 7–10 mg; 30–200 mg[82]
Zinc Pumpkin and squash seeds 
nuts; Soybean; Beef; 
Mollusks; Lamb
Reduces ROS in viral infections; Replication 
inhibition; Immunomodulatory effects; 
Antibody production; NK cell activity; 
Cytokine production by mononuclear cells; 
Chemotaxis response reduction; Neutrophil 
respiratory burst reduction 
8–14 mg; 30–50 mg[43] NCT04335084[90] Zinc, vitamin D, vitamin C 12 wk and 
hydroxychloroquine for 1 d
Prevention of COVID-19 symptoms 
recorded in a daily diary
Sunflower seeds; Coconut 
meat; Mollusks; Salmon; 
Selenium Antioxidant balanceROS balance in 
inflammatory processes 
60–70 mg
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Turkey; Ham
Copper Cashew nuts; Tofu; 
Mushrooms; Beef; Oyster; 
Cereals; Roots, tubers: 
Sweet potato; Quinoa
Role in immunity antimicrobial action due to 
copper toxicity; Enhance macrophage activity 
in lung infection
900 μg
IRCT20200611047735N1[114] 160 mg curcumin; 2 wk Immune responses (IFN-γ, IL-17, IL-4 
and TGF-β)
Curcumin Rhizome of turmeric 
(Curcuma longa)
Antioxidant capacity; Virus-ACE2 interaction 
reduction; ACE2 level increase; Antiviral 
activities SARS-CoV-2 protease, spike 
glycoprotein-RBD and PD-ACE2 binding IRCT20121216011763N46
[115]
1000 mg curcumin + 10 mg piperine 
twice/day, 2 wk
Clinical symptoms, duration, severity, 
inflammatory mediators
Silymarin Milk thistle (Silybum 
marianum)
Antioxidant capacity; Anti-inflammatory; p38 
MAPK pathway antiviral 
NCT04394208[116] 420 mg/d; 3 divided doses Clinical outcome duration of mechanical 
ventilation hospitalization 
ACE2: Angiotensin converting enzyme 2; COVID-19: Coronavirus disease 2019; CRP: C-reactive protein; CT: Computed tomography; ESR: Erythrocyte sedimentation rate; IFN-γ: Interferon-gamma; IL: Interleukin; NK: Natural killer; PD: 
Protease domain; RAS: Renin-angiotensin system; RBD: Receptor binding domain; ROS: Reactive oxygen species; SARS-CoV-2: Severe acute respiratory syndrome-coronavirus-2; tab.: Tablet; TGF-β: Transforming growth factor-beta; TNF-α
: Tumor necrosis factor-alpha; WBC: White blood cell.
The immunomodulatory effect of this vitamin are well established, and the 
supplements seems to be useful in the prevention or treatment of COVID-19. Vitamin 
D supplementation stimulates the binding of angiotensin-II to the ACE2 receptor, 
thereby diminishing the number of SARS-CoV-2 particles that can bind to ACE2 
receptors and enter the cells[55,56]. Two meta-analysis reported that COVID-19 
patients with a low blood vitamin D levels have worse prognoses[57] and that the risk 
of SARS-CoV-2 infection was significantly increased in patients with low levels of 
vitamin D[58]. CRP, as marker of inflammation and the cytokine storm, was highly 
expressed in COVID-19 patients with severe symptoms and correlate with vitamin 
deficiency[59]. Therefore, vitamin D could act as an adjuvant therapeutic for the 
treatment of this novel virus[60]. Ongoing clinical trials of vitamin D supplementation
[61-66] in patients with COVID-19 are presented in Table 1.
Vitamin C
Vitamin C has a key antioxidant role, maintains cellular redox balance and protects 
against free radicals (ROS and RNS) during oxidative fight[67]. Also, vitamin C 
regenerates oxidized vitamin E, GSH and carotenoids, modifies pro-inflammatory 
cytokine production, and lower blood histamine. The meta-analysis reported that 
administration of high doses of vitamin C was associated with a reduction in-hospital 
mortality among patients with severe sepsis[68]. The hepatoprotective property of 
water soluble vitamin C is attributed to its antioxidant action, Animal models have 
lent strong evidence that vitamin C supplementation significantly decreases hepatic 
markers of oxidative stress, hepatocellular ballooning, and inflammation[69]. The 
prooxidant potential of vitamin C is enhanced with the presence of iron and copper 
catalysts in vitro. Through the Fenton reaction, the antiviral activity of vitamin C 
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increases, resulting in the formation of hydroxyl radicals from hydrogen peroxide. 
High intake of vitamin C may be an effective choice in the early treatment of COVID-
19[70,71]. Several clinical studies evaluating vitamin C infusion in patients with 
COVID-19 are in progress (Table 1)[72-76]. It is indisputable that consumption of citrus 
fruits and vegetables that contain vitamin C is important in supporting the immune 
system during the COVID-19 pandemic[77].
Vitamin E
Vitamin E is a well-known fat-soluble vitamin, with a high antioxidant potential, 
which combats free radicals by a chain-breaking effect and protects cells from 
oxidative damage. Also, vitamin E enhances production of IL-2 and reduces 
production of prostaglandin E. Thus, vitamin E indirectly saves T cell function[32]. In 
addition, blood level of vitamin E inversely correlates with the number of products of 
oxidative stress, which is in line with the degree of liver injury. The potential 
mechanisms of action of vitamin E against COVID-19 involve the antioxidant 
properties of vitamin E derivatives that increase the integrity of the cell membrane and 
improve the adaptive response of the immune system to viral infections of the 
respiratory tract[78]. Natural isomers of vitamin E, α and γ tocopherols also have ROS 
scavenging potential. Taking vitamin E with vitamin C or alone, facilitates the removal 
of free radicals formed in the liver tissue[50]. The results of a meta-analysis[79] 
revealed that vitamin E supplementation significantly reduced AST, ALT, steatosis, 
inflammation, and hepatocellular ballooning. Vitamin E is also shown to be effective 
for normalizing ALT levels in patients with chronic liver injury in doses of 600 mg, 
while 800 IU is recommended for nondiabetic patients with nonalcoholic steatohep-
atitis (commonly known as NASH)[80,81]. As reviewed by Sahin et al[43], 200 IU 
vitamin E has no effect on lower respiratory infection but treatment with 800 IJ 
increases resistance to respiratory infections. Vitamins E and C in combination have 
been suggested as a useful antioxidant therapy in treating critically ill COVID-19 
patients with gastric cardia complications. Major food sources of vitamin E and 
recommended dietary intake[82] are presented in Table 1.
Vitamins B6 and B12
Vitamin B6 is essential cofactor for metabolism of amino acids, which are structural 
components of cytokines. It has been shown that higher levels of the active form of 
vitamin B6, pyridoxal 5'-phosphate (PLP) in plasma with parallel reduction in liver 
PLP is linked to the lower inflammation rate[32]. Adequate vitamin B6 (and B12) supple-
mentation in COVID-19 patients has been included in current protocols for the 
treatment[83], in order to regulate the altered homocysteine metabolism caused by the 
corona virus. Vitamin B6 administration at higher doses can decrease levels of inflam-
matory markers such as the TNF-α and IL-6, as well as D-dimer values, preventing 
coagulopathy in COVID-19 patients[84]. Methylcobalamin supplements may improve 
clinical deterioration during SARS-CoV-2 infection and decrease COVID-19-related 
symptoms and organ damage[85]. Combination of vitamin B12 (500 μg), vitamin D 
(1000 IU) and magnesium supplements was also shown to reduce COVID-19 severity 
symptoms and reduce the need for oxygen and intensive care support[86].
Zinc
Zinc enhances the function of antioxidant proteins and it is well known on its 
antioxidant activity, including protection against ROS and RNS[43]. It also has a strong 
anti-inflammatory action, reduces proliferation of proinflammatory Th17 and Th9 
cells, and thus decreases release of proinflammatory cytokines such as TNF-α, IL-2 and 
IL-6. Zinc is potentially considered a major mineral during SARS-CoV-2 infection due 
to its dual immunomodulatory and antiviral effects. Indirect data suggest that zinc 
may decrease the activity of ACE2[43]. In NAFLD patients, with comorbidities such as 
old age, overweight, immune disturbance, diabetes and atherosclerosis, zinc deficiency 
and low body status may increase the risk of severe COVID-19 illness[34]. However, in 
the latest meta-analyses of 12 randomized control studies, the decrease of IL-6, 
increase of IL-2 and no ameliorative effects on TNF-α level due to zinc supple-
mentation has been found[87].
Recent studies have shown that zinc supplementation is able to decrease SARS-
CoV-2 infections, due to inhibition of viral uncoating, binding, and replication. It is 
reported by Finzi et al[88] that the clinical respiratory symptoms were improved in 
COVID-19 patients supplemented with high dose of zinc citrate, zinc gluconate or zinc 
acetate.  Roy et al[89] suggested the combined use of curcumin and zinc treatment. The 
authors speculated that zinc in synergy with curcumin might promote the synthesis of 
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ionophore complexes, leading to the synchronized and improved antiviral activity. 
Curcumas exert an antiviral effect by inhibiting entry of the virus into the cell, while 
zinc inhibits the RNA polymerase. Major food sources of zinc, recommended dietary 
intake[43], and ongoing study that examines the effect of zinc supplementation in 
preventing COVID-19 symptoms[90] are presented in Table 1.
Selenium
As a part of selenoproteins, selenium has essential role in regulation of redox 
reactions, particularly in suppression of ROS produced during oxidative stress. 
Deficiency of selenium in the diet, concomitant with elevated oxidative stress in the 
host tissue, may lead to alteration of viral genome. The activity of selenoproteins in 
antioxidant defense, affects function of host leukocytes and NK cells[43], while 
selenium deficiency alters  immune response by reducing proliferation of T cells, the 
lymphocyte-mediated toxicity, and NK cell activity[91]. Besides being pointed out as a 
promising treatment for COVID-19[92], crucial role of selenium in the SARS-CoV-2 
emergence and spread has been suggested. Low selenium status in the host affects the 
viral genome[93], leading to the virus becoming more virulent[92]. Dietary supple-
mentation of selenium can stimulate the activity of cytotoxic effector cells in COVID-19
[94].
The meta-analysis of antioxidants effects in COVID-19 patients revealed decreased 
mortality and the requirement of mechanical ventilation, but no shorter time in 
intensive care unit (ICU) due to antioxidant therapies (predominantly based in supple-
mentation of selenium)[95,96]. However, in meta-analysis performed by Allingstrup 
and Afshari[97], no clear results supporting beneficial effect of selenium supple-
mentation in critically ill patients, including less days on a ventilation and shorter ICU 
and hospital stay, was shown. The elevated ratio of thromboxane A2 to prostacyclin I2 
followed by vasoconstriction and blood coagulation, has been found in animal models 
deficient in selenium[93]. The same mechanism possible explains the venous 
thromboembolism in COVID-19 patients with selenium deficiency.
Iron 
Among many other physiological roles, iron is known to regulate production and 
action of cytokines. It is also involved in the generation of ROS in neutrophils, which 
presents pathogen-killing activity during oxidative burst[31]. In hepatitis C, enhanced 
hepcidin production favors viral persistence, while the inflammation during SARS-
CoV-2 infection might be associated with promotion of hepcidin production. Elevated 
hepcidin reduces iron uptake in the gut, thus diminishing the effect of iron supple-
mentation. Even more, the sequestration of iron in macrophages, hepatocytes and 
enterocytes, can be reduced by hepcidin[98]. When SARS-CoV-2 colonizes these cells, 
the accumulated iron is used for viral replication. Evidence in the context of SARS-
CoV, based on the previous studies, indicates that iron is important for viral 
replication, which is why iron is a promising adjuvant therapeutic agent in treating the 
SARS-CoV-2 infection[99].
Copper
Being a part of copper/zinc-superoxide dismutase, an enzyme essential for anti-ROS 
defense, copper accumulates at sites of inflammation and acts as a free-radical 
scavenger[100]. Due to its activity in maintaining intracellular antioxidant balance, an 
important role for copper in the inflammatory response has been suggested. In 
general, it is important for IL-2 production and response, as well as for antibody 
production. Between 80% and 95% of copper is transported by ceruloplasmin, the 
levels of which are increased in response to inflammation and infection. Changes in 
copper homeostasis are a crucial component of respiratory burst. Copper has 
distinctive antimicrobial properties and helps to destroy a broad range of microor-
ganisms[101]. It competes with zinc for the same absorption site, and the copper 
deficiency is likely to occur when zinc orally supplemented at high doses. Copper 
deficiency has been identified in liver disease, in NAFLD associated with insulin 
resistance, steatosis, and an accelerated progression of NASH[102,103]. Copper has 
proven to be capable of inactivating different types of viruses, such as influenza 
A/WSN/33 and recently SARS-CoV-2[104]. SARS-CoV-2 is very sensitive to the 
copper surface[105], thus copper may be proposed for supplementation during 
COVID-19 treatment[106].
Magnesium
Magnesium is involved in several functions in the body, including antioxidant 
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defense. It assists in DNA protection against oxidative damage and diminishes the 
production of superoxide anion radical[31]. It is hypothesized that a low magnesium 
status may encourage transition from mild to critical clinical manifestations of the 
SARS-CoV-2 infection[107]. Magnesium also maintains proper lung function and 
reduces the risk of airway hyper-reactivity. It has been noticed that magnesium 
deficiency is related to reduced activity of immune cells and increased levels of IL-6, 
which is recognized as a key player in the COVID-19 associated cytokine storm[108]. 
According to a recent study by Tan et al[86] , the concomitant oral supplementation of 
vitamin D, magnesium, and vitamin B12 decreases clinical deterioration in patients 
with COVID-19. It should be noted that magnesium has a relationship to vitamin D 
physiology. This suggests that magnesium could contribute to the beneficial effects of 
vitamin D on COVID-19 outcomes.
Polyphenols 
Polyphenols are a large class of bioactive compounds from plants, which exert 
protective effects against oxidative stress, ultraviolet radiations, and different 
pathogens. Although there are more than 8000 polyphenolic compounds, all of them 
contain one or more phenolic rings with hydroxyl groups. The most common 
polyphenols are flavonoids (including, flavonols, isoflavones, flavones, flavanones, 
flavan-3-ols and anthocyanins), while nonflavonoids are phenolic acids (gallic, ellagic, 
chlorogenic or hydoxycinnamic), stilbenes (resveratrol), and lignans[109]. The antiviral 
activities of some polyphenolic compounds are well documented in the literature. 
Among the targeted viruses are hepatitis B and C viruses, herpes simplex virus-1, 
influenza A virus, and Epstein-Barr virus[110]. However, data on their effects on 
coronaviruses are still sparse.
Polyphenols could exert their anti-SARS-CoV-2 potential in several ways. The first 
one is inhibition of virus entry into the host cells. Since the spike (S) protein is the sole 
protein of coronaviruses responsible for its fusion with host cells, it is a meaningful 
target for antiviral therapies. Several polyphenols have demonstrated the interference 
with the S protein in vitro. In particular, luteolin and quercetin prevented SARS-CoV-2 
infection of Vero E6 cells[111], while emodin interfered with the interaction between S 
protein and its receptor ACE2 in the same cells[112]. Hesperidin has shown a similar 
effect on the S protein-ACE2 interaction as emodin, and curcumin and several 
polyphenols from Citrus species also possess a high affinity to S protein[110].
The fusion of S protein and ACE2 could also be prevented by targeting ACE2. Some 
polyphenols, such as curcumin and resveratrol, down-regulate expression and 
function of ACE2, thereby affecting severity of COVID-19. Further, Jena et al[113] 
recently published a computational study that showed flavonoids such as catechin and 
curcumin could bind the ACE2, impeding its interaction with the virus, but these 
implications have not been confirmed in vivo so far. Ongoing studies that examine the 
effect of curcumin and silymarin supplementation on clinical outcomes in COVID-19 
patients[114-116] are presented in Table 1.
Considering that ACE2 is abundantly expressed in the liver, this organ represents a 
potential target for direct infection and cytotoxicity caused by an active viral 
replication in hepatic cells[117]. Accordingly, persons with chronic liver disease can 
have serious consequences on health after SARS-CoV-2 infection, and polyphenols 
dietary intake could diminish these complications.
Aloe vera is one of the nutraceuticals with the strongest antiviral potential, with 
quercetin and kaempferol as the most active components against viruses. They both 
effectively reduce the viral replication of the influenza virus in vitro, and also reduce 
oxidative damage in the lungs and liver of infected mice[118]. Therefore, quercetin and 
kaempferol are good candidates for preclinical and clinical studies on the liver 
protection in SARS-CoV-2 infection.
Green tea and coffee are commonly consumed beverages worldwide and important 
sources of polyphenols. The polyphenols from green tea: Gallocatechin-3-gallate, 
epigallocatechin gallate, and epicatechingallate are recognized as potential weapon to 
battle SARS-CoV-2[119]. Moreover, both coffee and green tea have been shown to 
lower prevalence of metabolic syndrome, type 2 diabetes, and NAFLD[120].
Another mechanism for the beneficial effects of polyphenols in COVID-19 is the 
suppression of inflammatory response of the host. The above-mentioned cytokine 
storm, that has been responsible for lethal outcome in many patients worldwide, may 
be reduced by several polyphenols, including curcumin, resveratrol, emodin, epigal-
locatechin, gallate, naringenin, apigenin, and kaempferol[121]. All these polyphenols 
have shown potential to reduce level of proinflammatory cytokines in vitro and in vivo; 
although, their beneficial effects against SARS-CoV-2 need to be confirmed in clinical 
studies.
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The severe inflammatory response could also lead to immune-mediated damage of 
the liver[118]. In line with this, polyphenol mediates the body’s fight against the 
cytokine storm, which would protect the liver as well. Nevertheless, clinical studies on 
the hepatoprotective potential of different polyphenols in patients with COVID-19 are 
urgently needed to confirm this hypothesis.
Omega-3 fatty acids
Fatty acids are important players in hepatic lipid metabolism. Omega-3 fatty acids 
promote fat oxidation and decrease endogenous lipid synthesis by altering gene 
expression[122]. Patients with liver ALD have low levels of omega-3 fatty acids[123]. 
Despite genetic and anthropometric factors that could influence their benefits, 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) possess a strong anti-
inflammatory potential. Thus, a dietary intake of 250 mg/d is recommended for 
maintaining optimal health[36]. A study by Zheng et al[124] showed a statistically 
significant association between NAFLD and the severity of COVID-19 in obese 
patients and those with metabolic syndrome and fatty liver, while a study by 
Mahamid et al[47] showed that NAFLD is a significant risk factor for severe COVID-19 
independently of both sex or metabolic syndrome. Also, NAFLD patients, in particular 
those with associated obesity, commonly have an impaired omega-3 fatty acid level 
and an increased omega-6/omega-3 ratio that can be ameliorated by a nutritional 
intervention[125,126].
The European Society for Parenteral and Enteral Nutrition has recently declared 
that omega-3 fatty acids can increase oxygenation in COVID-19 patients[127,128]. 
Bistrian[129] proposed parenteral supplementation with high doses of EPA and DHA 
(4–6 g/d), for treatment of patients with severe COVID-19, to inhibit cytokine storm 
and reduce the inflammation. The possible benefits and risk of omega-3 fatty acid 
intervention for patients with COVID-19 have been reviewed[130]. The authors 
concluded that although EPA and DHA may positively affect resolution of inflam-
mation and recovery in patients with COVID-19, excess of EPA and/or DHA can 
induce LPO of cell membranes, resulting in cell damage due to elevated oxidative 
stress. This could be prevented by a concomitant supplementation with antioxidants, 
such as vitamin C and E[30,36]. However, based on the clinical trials that have been 
completed to date, it is still difficult to determine the optimal dose, route and timing of 
omega-3 fatty acids administration in COVID-19 patients. Until randomized clinical 
test data are validated, omega-3 fatty acid supplementation, especially at high doses, 
must be performed carefully in patients with COVID-19.
Dietary patterns 
The COVID-19 pandemic provides nutrition researchers with new opportunities to 
keep the public, especially those in high-risk groups, constantly informed about the 
potential benefits of good nutrition and healthy eating habits for prevention and 
therapy in COVID-19[40,131]. The most vulnerable are the elderly, due to a declined 
gastrointestinal uptake of micronutrients and macronutrients[132]. Many studies have 
shown association between a high intake of plant foods, fruit and vegetables and low 
levels of inflammatory parameters.
There is strong evidence of a favorable impact of the Mediterranean diet on IL-6 and 
CRP values[133]. Traditionally, the Mediterranean diet is characterized by low intake 
of simple carbohydrates, high consumption of olive oil, fiber, fresh fruit and 
vegetables, legumes, whole grains, olives, nuts and fish, moderate consumption of 
dairy products and poultry, low intake of red meat, many condiments and spices, and 
regular but moderate wine intake. Oleic acid consumption, which is abundant in olive 
oil, is also a feature. These components directly affect the synthesis of various 
antioxidant enzymes and may reduce liver tissue damage generated by oxidative 
stress[134].
Numerous studies have also shown the anti-inflammatory effect of the dietary 
approach stop hypertension (referred to as DASH) diet[135]. The ability of nutrients 
rich in antioxidants (bayberry juice, chocolate, onion, lettuce, and tomato products) to 
increase TAC in plasma and thereby reduce NAFLD through modifications of 
oxidative stress is well documented[34]. However, proper nutrition and nutrition 
support can help battle against COVID-19 by improving immune responses and aiding 
inflammatory processes[40,136].
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CONCLUSION
Foods rich in vitamins, minerals, polyphenols and other bioactive compounds may 
decrease inflammatory pathway activity and prevent liver damage in COVID-19 
patients. An important additional aspect is their ability to control oxidative stress. 
Antioxidants supplementation during the COVID-19 pandemic crisis should respect 
nutritional status and serum levels of relevant nutrients in patients. It is essential to 
recognize nutritional deficiencies in COVID-19 patients, and to intervene to improve 
their status. Constant public informing about balanced diet and healthy eating habits 
is important in the prevention of SARS-CoV-2 infection.
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